Latest Insider Transactions at Becton Dickinson & CO (BDX)
This section provides a real-time view of insider transactions for Becton Dickinson & CO (BDX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BECTON DICKINSON & CO to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BECTON DICKINSON & CO's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 26
2025
|
Michael Feld EVP, CRO & Pres. Life Sciences |
SELL
Open market or private sale
|
Direct |
74
-0.45%
|
$14,504
$196.08 P/Share
|
|
Dec 17
2025
|
Michael David Garrison EVP & Pres Med.Essntl&BioPharm |
SELL
Open market or private sale
|
Direct |
629
-4.58%
|
$123,284
$196.03 P/Share
|
|
Dec 01
2025
|
Michael Feld EVP, CRO & Pres. Life Sciences |
SELL
Open market or private sale
|
Direct |
75
-0.45%
|
$14,475
$193.36 P/Share
|
|
Dec 01
2025
|
Robert Luther Huffines Director |
BUY
Grant, award, or other acquisition
|
Direct |
180
+50.0%
|
-
|
|
Dec 01
2025
|
Jacqueline Wright Director |
BUY
Grant, award, or other acquisition
|
Direct |
180
+50.0%
|
-
|
|
Nov 26
2025
|
Pavan Kumar Mocherla EVP & President, Greater Asia |
BUY
Grant, award, or other acquisition
|
Direct |
2,916
+20.67%
|
-
|
|
Nov 26
2025
|
David Shan EVP and Chief ISC Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
134
-1.47%
|
-
|
|
Nov 26
2025
|
David Shan EVP and Chief ISC Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,529
+20.19%
|
-
|
|
Nov 26
2025
|
Shana Carol Neal EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,454
-10.32%
|
-
|
|
Nov 26
2025
|
Shana Carol Neal EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,252
+18.92%
|
-
|
|
Nov 26
2025
|
Roland Goette EVP and President, EMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
138
-0.79%
|
-
|
|
Nov 26
2025
|
Roland Goette EVP and President, EMEA |
BUY
Grant, award, or other acquisition
|
Direct |
3,143
+8.61%
|
-
|
|
Nov 26
2025
|
Michael Feld EVP, CRO & Pres. Life Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
419
-2.45%
|
-
|
|
Nov 26
2025
|
Michael Feld EVP, CRO & Pres. Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
8,829
+34.08%
|
-
|
|
Nov 26
2025
|
Michael David Garrison EVP & Pres Med.Essntl&BioPharm |
SELL
Payment of exercise price or tax liability
|
Direct |
1,769
-11.41%
|
-
|
|
Nov 26
2025
|
Michael David Garrison EVP & Pres Med.Essntl&BioPharm |
BUY
Grant, award, or other acquisition
|
Direct |
10,616
+27.11%
|
-
|
|
Nov 26
2025
|
Christopher Del Orefice EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,245
-15.59%
|
-
|
|
Nov 26
2025
|
Christopher Del Orefice EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,006
+18.07%
|
-
|
|
Nov 26
2025
|
Bilal Muhsin EVP & President Connected Care |
BUY
Grant, award, or other acquisition
|
Direct |
9,530
+30.47%
|
-
|
|
Nov 26
2025
|
Richard Byrd EVP & President Interventional |
SELL
Payment of exercise price or tax liability
|
Direct |
1,719
-11.04%
|
-
|
|
Nov 26
2025
|
Richard Byrd EVP & President Interventional |
BUY
Grant, award, or other acquisition
|
Direct |
8,832
+23.06%
|
-
|
|
Nov 26
2025
|
Thomas E Polen Jr Chairman, CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
17,421
-14.18%
|
-
|
|
Nov 26
2025
|
Thomas E Polen Jr Chairman, CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
22,521
+15.49%
|
-
|
|
Nov 26
2025
|
Pamela L. Spikner SVPController & Chief Acct Off |
BUY
Grant, award, or other acquisition
|
Direct |
1,234
+39.17%
|
-
|
|
Nov 07
2025
|
Bertram L Scott Director |
SELL
Open market or private sale
|
Direct |
217
-0.6%
|
$38,192
$176.58 P/Share
|
|
Oct 27
2025
|
Michael Feld EVP, CRO & Pres. Life Sciences |
SELL
Open market or private sale
|
Direct |
57
-0.69%
|
$10,602
$186.01 P/Share
|
|
Sep 26
2025
|
Michael Feld EVP, CRO & Pres. Life Sciences |
SELL
Open market or private sale
|
Direct |
58
-0.69%
|
$10,498
$181.03 P/Share
|
|
Sep 10
2025
|
Claire Fraser Director |
SELL
Open market or private sale
|
Direct |
917
-3.96%
|
$171,479
$187.5 P/Share
|
|
Sep 01
2025
|
Christopher Del Orefice EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
278
-1.29%
|
-
|
|
Sep 01
2025
|
Richard Byrd EVP & President Interventional |
SELL
Payment of exercise price or tax liability
|
Direct |
216
-3.11%
|
-
|
|
Aug 22
2025
|
Michael Feld EVP, CRO & Pres. Life Sciences |
SELL
Open market or private sale
|
Direct |
57
-0.68%
|
$11,229
$197.99 P/Share
|
|
Aug 20
2025
|
Michael Feld EVP, CRO & Pres. Life Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
773
-8.41%
|
-
|
|
Aug 11
2025
|
Gregory Hayes Director |
BUY
Open market or private purchase
|
Direct |
5,250
+46.48%
|
$1,002,750
$191.57 P/Share
|
|
Aug 08
2025
|
Claire Fraser Director |
SELL
Open market or private sale
|
Direct |
863
-3.59%
|
$165,696
$192.3 P/Share
|
|
Jul 18
2025
|
Michael David Garrison EVP & Pres Med.Essntl&BioPharm |
SELL
Open market or private sale
|
Direct |
1,185
-9.76%
|
$213,300
$180.89 P/Share
|
|
Jul 18
2025
|
Michael David Garrison EVP & Pres Med.Essntl&BioPharm |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,175
-46.01%
|
$931,500
$180.29 P/Share
|
|
Jul 18
2025
|
Michael David Garrison EVP & Pres Med.Essntl&BioPharm |
BUY
Exercise of conversion of derivative security
|
Direct |
6,360
+36.12%
|
$934,920
$147.68 P/Share
|
|
Jul 02
2025
|
Bilal Muhsin EVP & President Connected Care |
BUY
Grant, award, or other acquisition
|
Direct |
12,221
+50.0%
|
-
|
|
Jun 02
2025
|
David Shan EVP and Chief ISC Officer |
SELL
Open market or private sale
|
Direct |
1,166
-20.31%
|
$199,386
$171.19 P/Share
|
|
Apr 09
2025
|
Michael David Garrison EVP & Pres Med.Essntl&BioPharm |
SELL
Open market or private sale
|
Direct |
479
-8.93%
|
$94,363
$197.28 P/Share
|
|
Apr 04
2025
|
Shana Carol Neal EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,886
-12.24%
|
-
|
|
Mar 26
2025
|
Gregory Hayes Director |
BUY
Grant, award, or other acquisition
|
Direct |
796
+50.0%
|
-
|
|
Mar 18
2025
|
Richard Byrd EVP & President Interventional |
SELL
Open market or private sale
|
Direct |
459
-6.19%
|
$105,570
$230.0 P/Share
|
|
Mar 12
2025
|
Richard Byrd EVP & President Interventional |
SELL
Open market or private sale
|
Direct |
1,940
-20.75%
|
$434,560
$224.91 P/Share
|
|
Mar 01
2025
|
Michael David Garrison EVP & Pres Med.Essntl&BioPharm |
SELL
Payment of exercise price or tax liability
|
Direct |
178
-3.21%
|
-
|
|
Feb 12
2025
|
Bertram L Scott Director |
SELL
Open market or private sale
|
Direct |
700
-1.91%
|
$158,900
$227.99 P/Share
|
|
Feb 10
2025
|
Jeffrey William Henderson Director |
BUY
Open market or private purchase
|
Direct |
1,500
+15.76%
|
$349,500
$233.62 P/Share
|
|
Jan 28
2025
|
William M Brown Director |
BUY
Grant, award, or other acquisition
|
Direct |
930
+21.06%
|
-
|
|
Jan 28
2025
|
Catherine M Burzik Director |
BUY
Grant, award, or other acquisition
|
Direct |
930
+6.12%
|
-
|
|
Jan 28
2025
|
Christopher Ian Montague Jones Director |
BUY
Grant, award, or other acquisition
|
Direct |
930
+3.94%
|
-
|